Cullinan Therapeutics (CGEM) Liabilities and Shareholders Equity (2020 - 2026)

Cullinan Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $403.0 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 30.48% year-over-year to $403.0 million in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 26.82% decrease from a year earlier, with the FY2025 full-year figure at $448.4 million, down 27.89% from the prior year.
• Liabilities and Shareholders Equity declined to $403.0 million in Q1 2026 per CGEM's latest filing, from $448.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $681.2 million in Q2 2024 and bottomed at $403.0 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $520.3 million (2025), against an average of $537.7 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 43.69% in 2022 and slumped 30.48% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $561.1 million in 2022, then decreased by 13.71% to $484.2 million in 2023, then grew by 28.43% to $621.8 million in 2024, then dropped by 27.89% to $448.4 million in 2025, then decreased by 10.12% to $403.0 million in 2026.
• Per Business Quant, the three latest CGEM Liabilities and Shareholders Equity figures stand at $403.0 million (Q1 2026), $448.4 million (Q4 2025), and $484.1 million (Q3 2025).